Deep Breaths: Updates from CHEST

A multidisciplinary panel including a medical oncologist, a thoracic surgeon, and an interventional pulmonologist will discuss the role of lung cancer teams in their thoracic oncology practices. The panelists will review their management of patients with lung cancer during the COVID-19 pandemic, including the impact of delayed procedures and telemedicine on patient outcomes.

Two internationally known medical and radiation oncologists will discuss ongoing and recent clinical trials and offer their perspectives on how they will impact thoracic oncology practice. The panelists will also discuss current guidelines for managing patients with advanced lung cancer and emphasize the role of tissue and blood biomarkers.

Expert pathologists and a medical oncologist will discuss current guidelines and their own practices regarding the role of liquid biopsy and comprehensive genetic and PD-L1 testing in the management of advanced lung cancer. The panelists will also explore various strategies for optimizing the quantity and quality of cytology and small volume biopsy specimens.

Two internationally known interventional pulmonologists will discuss current guidelines and their own experiences regarding sampling of lung lesions and mediastinal adenopathy. Specifically, the panelists will discuss the pros and cons of various diagnostic strategies and sampling techniques, including transcutaneous and bronchoscopic biopsies. This interactive webinar will offer the opportunity for learners to ask questions prior to and during the event. Learning is augmented by a few follow-up quizzes weeks after the webinar, a strategy proven to improve knowledge gain and retention.

There are many barriers to reaching a definitive diagnosis for idiopathic pulmonary fibrosis (IPF). To learn more about these obstacles—and how we can overcome them—Dr. David Schulman from the American College of Chest Physicians joins Dr. Tim Hernandez from the University of Texas Health Sciences Center and Dr. Andrew Limper from the Mayo Clinic to discuss the diagnosis of IPF.

This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by Three Lakes Foundation.

Click here to receive updates on Bridging Specialties™ and how you can be involved.

Do cytokines play a role in chronic rhinosinusitis? Dr. Peter Howarth is joined by Dr. Katie Buchheit, an Associate Professor of Medicine at Harvard Medical School, and Professor Philippe Gevaert, an ENT specialist at the Department of Otorhinolaryngology at Ghent University and the Upper Airway Research Laboratory, to explore the role of inflammatory mediators in the progression of chronic rhinosinusitis with nasal polyps.

This is a nonpromotional, non-CME disease state educational podcast brought to you by the American College of CHEST Physicians in collaboration with and paid for by GSK.

Type 2 inflammation can be challenging to identify. What should we be looking for in our patients with severe asthma and COPD? Joining Dr. Peter Howarth to discuss identifying this type of inflammation are Dr. Geoffrey Chupp from the Yale School of Medicine and Dr. Ian Pavord from the University of Oxford.

This is a nonpromotional, non-CME disease state educational podcast brought to you by the American College of CHEST Physicians in collaboration with and paid for by GSK.

Inhalers are one of the most common methods of delivery for the treatment of COPD, but is it the best option for all of our patients? Associate Professor of Pulmonary Critical Care at Baylor College of Medicine, Dr. Muhammad Adrish, reviews LAMA use for COPD patients with Dr. Navitha Ramesh, Assistant Professor at Drexel University College of Medicine.

This episode is produced in partnership with the American College of CHEST Physicians and is sponsored by Viatris Inc.

On average, more than two-thirds of patients with chronic obstructive pulmonary disease (COPD) make at least one error in using an inhaler device. Fortunately, nebulized long-acting muscarinic antagonists (LAMAs) can help our patients overcome this common challenge in COPD care. That’s why Drs. Megan Conroy and Farrukh Abbas come together to talk about the GOLD treatment guidelines, strategies for reducing patient hesitancy regarding nebulized LAMAs, and more.

This episode is produced in partnership with the American College of CHEST Physicians and is sponsored by Viatris Inc.

Severe asthma is an uncontrolled disease that can be difficult to diagnose. To help us overcome this obstacle, Dr. Tom Corbridge joins Dr. Michael Wechsler from National Jewish Health in Denver to discuss the challenges we face while trying to diagnose severe asthma.

This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.